BACKGROUND: Ventricular arrhythmias remain a lethal complication of acute coronary syndromes (ACS). However, the incidence and prognosis of sustained ventricular tachycardia/ventricular fibrillation (VT/VF) in contemporary non-ST-segment-elevation (NSTE) ACS populations are not well described. METHODS AND RESULTS: We examined the incidence of VT/VF and subsequent survival among 9211 patients enrolled in the Early Glycoprotein IIb/IIIa Inhibition in NSTE ACS (EARLY ACS) trial. The cumulative incidence of VT/VF was 1.5% (n=141); 0.6% (n=55) had VT/VF ≤48 hours after enrollment, and 0.9% (n=86) had VT/VF >48 hours after enrollment. Patients with VT/VF more frequently had prior heart failure, an ejection fraction <30%, and triple-vessel coronary artery disease. Predictors of sustained VT/VF were similar regardless of the timing of VT/VF (≤48 versus >48 hours). Patients with VT/VF ≤48 hours after enrollment had higher 30-day mortality than those who did not have VT/VF ≤48 hours (13.0% versus 2.2%; adjusted odds ratio, 6.73; 95% confidence interval, 2.68-16.9). The increased risk of death associated with VT/VF ≤48 hours persisted at 1 year. The risk of mortality, relative to patients without VT/VF, was greater for patients with VT/VF >48 hours (hazard ratio, 20.70; 95% confidence interval, 15.39-27.85) than for those with earlier VT/VF (hazard ratio, 7.45; 95% confidence interval, 4.60-12.08; P=0.0003). The frequency of arrhythmic death was higher in patients with VT/VF than in those without VT/VF (26.4% versus 6.9%). CONCLUSIONS: Sustained VT/VF is infrequent after NSTE ACS but is as likely to occur after 48 hours as within the first 48 hours. The marked increase in all-cause death among NSTE ACS patients with both early and late sustained VT/VF raises important considerations for aggressive monitoring beyond 48 hours and interventions to prevent arrhythmic death in these patients. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00089895.
RCT Entities:
BACKGROUND:Ventricular arrhythmias remain a lethal complication of acute coronary syndromes (ACS). However, the incidence and prognosis of sustained ventricular tachycardia/ventricular fibrillation (VT/VF) in contemporary non-ST-segment-elevation (NSTE) ACS populations are not well described. METHODS AND RESULTS: We examined the incidence of VT/VF and subsequent survival among 9211 patients enrolled in the Early Glycoprotein IIb/IIIa Inhibition in NSTE ACS (EARLY ACS) trial. The cumulative incidence of VT/VF was 1.5% (n=141); 0.6% (n=55) had VT/VF ≤48 hours after enrollment, and 0.9% (n=86) had VT/VF >48 hours after enrollment. Patients with VT/VF more frequently had prior heart failure, an ejection fraction <30%, and triple-vessel coronary artery disease. Predictors of sustained VT/VF were similar regardless of the timing of VT/VF (≤48 versus >48 hours). Patients with VT/VF ≤48 hours after enrollment had higher 30-day mortality than those who did not have VT/VF ≤48 hours (13.0% versus 2.2%; adjusted odds ratio, 6.73; 95% confidence interval, 2.68-16.9). The increased risk of death associated with VT/VF ≤48 hours persisted at 1 year. The risk of mortality, relative to patients without VT/VF, was greater for patients with VT/VF >48 hours (hazard ratio, 20.70; 95% confidence interval, 15.39-27.85) than for those with earlier VT/VF (hazard ratio, 7.45; 95% confidence interval, 4.60-12.08; P=0.0003). The frequency of arrhythmic death was higher in patients with VT/VF than in those without VT/VF (26.4% versus 6.9%). CONCLUSIONS: Sustained VT/VF is infrequent after NSTE ACS but is as likely to occur after 48 hours as within the first 48 hours. The marked increase in all-cause death among NSTE ACS patients with both early and late sustained VT/VF raises important considerations for aggressive monitoring beyond 48 hours and interventions to prevent arrhythmic death in these patients. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00089895.
Authors: Sean D Pokorney; Christina Radder; Phillip J Schulte; Sana M Al-Khatib; Pierluigi Tricocci; Frans Van de Werf; Stefan K James; Christopher P Cannon; Paul W Armstrong; Harvey D White; Robert M Califf; C Michael Gibson; Robert P Giugliano; Lars Wallentin; Kenneth W Mahaffey; Robert A Harrington; L Kristin Newby; Jonathan P Piccini Journal: Am Heart J Date: 2015-09-12 Impact factor: 4.749
Authors: Alexander C Fanaroff; Eric D Peterson; Anita Y Chen; Laine Thomas; Jacob A Doll; Christopher B Fordyce; L Kristin Newby; Ezra A Amsterdam; Mikhail N Kosiborod; James A de Lemos; Tracy Y Wang Journal: JAMA Cardiol Date: 2017-01-01 Impact factor: 14.676
Authors: Patrizia Natale; Suetonia C Palmer; Valeria M Saglimbene; Marinella Ruospo; Mona Razavian; Jonathan C Craig; Meg J Jardine; Angela C Webster; Giovanni Fm Strippoli Journal: Cochrane Database Syst Rev Date: 2022-02-28
Authors: Arunashis Sau; Amit Kaura; Amar Ahmed; Kiran H K Patel; Xinyang Li; Abdulrahim Mulla; Benjamin Glampson; Vasileios Panoulas; Jim Davies; Kerrie Woods; Sanjay Gautama; Anoop D Shah; Paul Elliott; Harry Hemingway; Bryan Williams; Folkert W Asselbergs; Narbeh Melikian; Nicholas S Peters; Ajay M Shah; Divaka Perera; Rajesh Kharbanda; Riyaz S Patel; Keith M Channon; Jamil Mayet; Fu Siong Ng Journal: J Am Heart Assoc Date: 2022-03-08 Impact factor: 6.106
Authors: Jaihoon Amon; Graham C Wong; Terry Lee; Joel Singer; John Cairns; Jay S Shavadia; Christopher Granger; Kenneth Gin; Tracy Y Wang; Sean van Diepen; Christopher B Fordyce Journal: J Am Heart Assoc Date: 2022-09-03 Impact factor: 6.106
Authors: Orianne Weizman; Eloi Marijon; Kumar Narayanan; Serge Boveda; Pascal Defaye; Raphael Martins; Jean-Claude Deharo; Gabriel Laurent; Didier Klug; Nicolas Sadoul; Meleze Hocini; Nicolas Mansencal; Frédéric Anselme; Antoine Da Costa; Philippe Maury; Jean Ferrières; François Schiele; Tabassome Simon; Nicolas Danchin Journal: J Am Heart Assoc Date: 2022-08-26 Impact factor: 6.106
Authors: Jarosław Gorący; Paweł Stachowiak; Arkadiusz Krejczy; Patrycja Piątek; Iwona Gorący Journal: Int J Environ Res Public Health Date: 2022-02-23 Impact factor: 3.390